Masimo softFlow™

Masimo softFlow™

Masimo softFlow™

 

Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD.

Bräunlich et al. Int J Chron Obstruct Pulmon Dis 2019;(14):1411-1421.

Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls.

Biselli et al. Eur Respir J 2018;51:1702251.

Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study.

Biselli et al. J Appl Physiol (1985). 2017;122(1):82-88.

Nasal highflow improves ventilation in patients with COPD.

Bräunlich J et al.
Int J Chron Obstruct Pulmon Dis. 2016;(11):1077-1085.

Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report.

Bräunlich J et al.
Multidiscip Respir Med. 2015;10(1):27. 

Nasal high-flow in acute hypercapnic exacerbation of COPD

Bräunlich J, Wirtz H.
Int J Chron Obstruct Pulmon Dis. 2018;13:3895-3897.
doi:10.2147/COPD.S185001

Nasal highflow eliminates CO2 from lower airways.

Bräunlich J, Goldner F, Wirtz H.
Respir Physiol Neurobiol. 2017;242:86-88. doi:10.1016/j.resp.2017.03.012

Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients.

Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H.
Respiration. 2013;85(4):319-325. doi:10.1159/000342027

Mechanisms of nasal high flow on ventilation during wakefulness and sleep.

Mündel T, Feng S, Tatkov S, Schneider H.. J Appl Physiol (1985). 2013;114(8):1058-1065.
doi:10.1152/japplphysiol.01308.2012

Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD.

Bräunlich et al. Int J Chron Obstruct Pulmon Dis 2019;(14):1411-1421.

Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls.

Biselli et al. Eur Respir J 2018;51:1702251.

Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study.

Biselli et al. J Appl Physiol (1985). 2017;122(1):82-88.

Nasal highflow improves ventilation in patients with COPD.

Bräunlich J et al.
Int J Chron Obstruct Pulmon Dis. 2016;(11):1077-1085.

Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report.

Bräunlich J et al.
Multidiscip Respir Med. 2015;10(1):27. 

Nasal high-flow in acute hypercapnic exacerbation of COPD

Bräunlich J, Wirtz H.
Int J Chron Obstruct Pulmon Dis. 2018;13:3895-3897.
doi:10.2147/COPD.S185001

Nasal highflow eliminates CO2 from lower airways.

Bräunlich J, Goldner F, Wirtz H.
Respir Physiol Neurobiol. 2017;242:86-88. doi:10.1016/j.resp.2017.03.012

Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients.

Bräunlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H.
Respiration. 2013;85(4):319-325. doi:10.1159/000342027

Mechanisms of nasal high flow on ventilation during wakefulness and sleep.

Mündel T, Feng S, Tatkov S, Schneider H.. J Appl Physiol (1985). 2013;114(8):1058-1065.
doi:10.1152/japplphysiol.01308.2012

Schlüssel für klinische Nachweise:

Weist auf ein PDF-Dokument hin

Weist auf eine Kurzfassung oder Präsentation hin

Weist auf einen von einem Kollegen bewerteten Artikel hin

Doppelte Kurzfassungen oder Veröffentlichungen sind nicht inbegriffen

This section is intended to provide access to clinical studies conducted using Masimo noninvasive technologies, parameters, and products. We cannot guarantee that all published clinical studies, abstracts and research are listed here. To view individual clinical studies please click on the appropriate tab

Some uses of the manufacturer’s devices described in the information may note have been approved or cleared by the FDA. See manufacturer labeling for the indications in the product’s cleared indications for use statement.

Der klinische Nachweis wird vorgelegt, um die Leistungsfähigkeit und Genauigkeit von Technologien Masimo zu veranschaulichen. Laut US-Bundesgesetz dürfen Medizinprodukte von Masimo nur von Ärzten oder auf deren Anordnung hin verkauft werden.

PLCO-004774/PLMM-11836B-0421